Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Abstract

Pembrolizumab therapy was associated with cutaneous AEs in 42% of patients. The development of cutaneous AEs, especially of hypopigmentation in patients with melanoma, could point toward better treatment response.